• Home
  • Search Results

Search Results

Young Adult (18-34)
Cancer
417 studies match your search
Open

Phase 1/1b study for people with advanced or metastatic cancer

Do you have advanced or metastatic non small cell lung cancer, squamous cell carcinoma of the head and neck, colorectal cancer, or renal cell carcionma? Have you tried previous therapies that did not work? If so, you may be able to take part in this study. Investigational study drug is provided.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Phase 1 Trials (all cancers))
Open

Reduced Treatment after Surgery in Triple Negative Breast Cancer Patients

Do you have triple negative breast cancer? Have you had surgery following chemotherapy? You may be able to participate in a study to find out if stopping pembrolizumab infusions after surgery is just as effective at reducing your risk of cancer recurrence.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Breast)
Open

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Lymphoma)
  • Transplant

Acute Lymphoblastic Leukemia Study

The purpose of this study is to find out if we can improve the chance of your leukemia going away (remission) and lower the chance of your leukemia coming back (relapsing) by combining two drugs for acute lymphoblastic leukemia. In this study you will be given the first study drug (Inotuzumab Ozogamicin) for up to 7 weeks and then a second leukemia drug (Blinatumomab) for up to 31 weeks.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Not currently enrolling

Study for Cancer Patients With KRAS G12C Genetic Mutation

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lung)
Visit Location
100% Remote (online, phone, text)

Newly Diagnosed Secondary AML Research Study

This is a research study to find out if giving a combination of drugs (tagraxofusp and azacitidine) will treat your leukemia and keep it inactive for a period of time.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Open

NRG-GU010 GUIDANCE

Have you been diagnosed with unfavorable risk prostate cancer? Are you looking for treatment options? If so, you may be able to participate in a clinical trial examining different treatment options for prostate cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Gender Inclusive
Study Interest
  • Cancer (Prostate)
Open

Untreated Follicular Lymphoma Study

Have you been recently diagnosed with follicular lymphoma (a type of non-Hodgkin lymphoma)? You may be able to take part in a research study to learn more about the safety and tolerability of an experimental drug called odronextamab.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Phase II/III research study to determine how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck)
Open

LUNGMAP - Non-Small Cell Lung Cancer Research

Do you have metastatic or recurrent lung cancer? Have you already been treated with chemotherapy or immunotherapy? If so, you may qualify for the LungMap protocol, which will help us identify clinical trials you may be eligible for.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Lung)
  • Lungs and Breathing
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research